Improving Medication Therapy Through a Digital Interdisciplinary Medicine Therapy Optimisation Model
- Conditions
- Drug Use
- Interventions
- Other: digital interdisciplinary intervention
- Registration Number
- NCT05629936
- Lead Sponsor
- Umeå University
- Brief Summary
This study investigates if a digital interdisciplinary medicine therapy optimisation (MTO) model in primary care can improve medication therapy, quality of life, medication adherence, and beliefs about medicines, among patients \>65 years living in sparsely populated areas. The intervention includes digital medication interviews, comprehensive medication reviews, interdisciplinary patient-centred discussions, and follow-ups.
- Detailed Description
Initially, a pilot study will be conducted to evaluate the feasibility of the method and to make appropriate adjustments to the study design before starting the main study. Patients that meet the inclusion criteria will be invited to participate in the study via letter. The patients will also receive three validated questionnaires; Medication Adherence Report Scale-5 (MARS-5), EuroQol-5 Dimension-5 Level questionnaire (EQ-5D-5L) and The Beliefs about Medicines Questionnaire (BMQ) to fill in prior to initiation of the study, to collect baseline data. The intervention consists of several steps and all meetings are digital. At first, the patient will have a medication interview with a clinical pharmacist, Next, the clinical pharmacist conducts a comprehensive medication review based on information from the interview and the participant's medical records and laboratory values. The clinical pharmacist and the participant's primary care physician will then have a joint discussion regarding preliminary medication management proposals and therapy management plans. The patient will be informed by their physician if any medication changes have been made. Digital follow-up meetings with the patient and the clinical pharmacist will take place 1-2, 4 and 12 weeks after the baseline consultation, and additionally if requested by the patient or if the pharmacist consider it necessary. The clinical pharmacist will also conduct repeated medical record reviews every second week during the 12-week intervention period. After the last follow-up at 12 weeks, the patient will be asked to fill in the three questionnaires: MARS-5, EQ-5D-5L and BMQ one more time.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 8
- Using 5 or more medications or recommended by the primary care physician (e.g. according to the use of certain medicines or conditions such as chronic kidney disease)
- Living at home (i.e not in a nursing home)
- Registered at certain primary healthcare centres in the rural areas of Västerbotten
- Do not speak Swedish or unable to communicate
- Has home care services
- Has a confirmed major neurocognitive disorder
- Receives palliative care
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description digital intervention digital interdisciplinary intervention Digital intervention
- Primary Outcome Measures
Name Time Method Identification and resolution of drug-related problems The 12-week intervention period Categorisation of drug-related problems according to a modified version of the Cipolle-Strand-Morley criteria 2012
Change in self-reported medication adherence: Medication Adherence Report Scale-5 (MARS-5) Baseline and 12 weeks Assessing self-reported medication adherence through the MARS-5 questionnaire. Total score ranging between 5 and 25, with higher scores indicating a higher level of medication adherence.
Change in self-reported health-related quality of life: EuroQol-5 Dimension-5 Level questionnaire (EQ-5D-5L) Baseline and 12 weeks Assessing health-related quality of life through the EQ-5D-5L-questionnaire. The questionnaire consists of five questions regarding self-perceived quality of life, and a visual analogue scale on which the respondents evaluate their own health status on a scale of 0-100.
Change in self-reported beliefs about medicines: The Beliefs about Medicines Questionnaire (BMQ) Baseline and 12 weeks Assessing beliefs about medicines through BMQ. The questionnaire consists of two different scales; BMQ-General assesses the respondent's beliefs about drugs in general and BMQ-Specific evaluates the individual's beliefs about medicines prescribed for their own use.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Storuman healthcare centre
🇸🇪Storuman, Sweden